Revance Therapeutics (RVNC)

Earnings in 2024 (TTM): -€0.15 Billion

According to Revance Therapeutics's latest financial reports the company's current earnings are €0.24 Billion. In 2023 the company made an earning of -€0.16 Billion, an increase over its 2022 earnings that were of -€0.3 Billion. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.

Earnings history for Revance Therapeutics from 2013 to 2024

Annual earnings

Year	Earnings	Change
2024 (TTM)	-€0.15 Billion	-8.96%
2023	-€0.16 Billion	-46.32%
2022	-€0.3 Billion	23.35%
2021	-€0.24 Billion	2.03%
2020	-€0.24 Billion	69.08%
2019	-€0.14 Billion	14.27%
2018	-€0.13 Billion	16.14%
2017	-€0.11 Billion	36.22%
2016	-€76.04 Million	22%
2015	-€62.33 Million	38.36%
2014	-€45.05 Million	40.12%
2013	-€32.15 Million

Earnings for similar companies or competitors

Company	Earnings	Earnings differencediff.	Country
MediciNova MNOV	-€10.36 Million	-92.32%	🇺🇸 USA
Johnson & Johnson JNJ	€27.93 B	-20,834.37%	🇺🇸 USA
Biogen BIIB	€1.64 B	-1,318.61%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Earnings for Revance Therapeutics (RVNC)

Earnings in 2024 (TTM): -€0.15 Billion